In 2025, the U.S. radiopharmaceutical market is expected to see continued growth, driven by aging populations, advancements in theranostics, an increased demand for targeted cancer treatments and an expansion of applications...more
The U.S. Food and Drug Administration (FDA) recently issued two new guidance documents governing details of the Accelerated Approval Program, including a focus on product withdrawal and requirements for ongoing confirmatory...more